Abionyx Pharma

ABNX.PA has a market price of 3.475 EUR and a market capitalization of 122,643,348.75 EUR, indicating a relatively small market presence. The company's price-to-book ratio is 27.18, which is significantly higher than the industry median, suggesting that the market is valuing the company's equity at a premium. The enterprise value to EBITDA ratio is negative at -22.83, reflecting the company's current unprofitability.

The company's profitability is a concern, with a return on equity of -1.2301 and a return on assets of -0.4232, both of which are below the industry median. The operating income is negative at -5,538,000 EUR, and the net income is also negative at -5,550,000 EUR, indicating that the company is not generating positive earnings. The gross profit of 534,000 EUR is modest compared to the company's revenue of 4,063,000 EUR, suggesting that the company is facing significant cost pressures.

ABNX.PA's revenue is concentrated in a single segment, as disclosed in the financial snapshot, with no specific geographic breakdown provided. The company's revenue concentration in a single segment increases its exposure to market-specific risks. The lack of geographic diversification could also limit the company's growth potential in new markets.

The company's growth trajectory is uncertain, with no specific revenue growth projections provided. The operating cash flow is negative at -2,933,000 EUR, and the free cash flow is also negative at -5,302,000 EUR, indicating that the company is not generating sufficient cash to fund its operations. The capital expenditure of -242,000 EUR suggests that the company is investing in its operations, but the negative cash flows indicate that the company may need to seek additional financing.

The risk assessment indicates that the company has a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt highlights the company's liquidity challenges. The debt-to-equity ratio of 0.84 suggests that the company is not overly leveraged, but the negative cash flows could lead to increased debt in the future.

Recent events, as reflected in the financial snapshot, show that the company is facing significant financial challenges. The negative operating and net income, combined with negative cash flows, indicate that the company is not currently profitable. The analyst estimates suggest a mean price target of 11.00 EUR, which is significantly higher than the current market price, indicating that analysts have a positive outlook on the company's future performance.